Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): german AIO KRK0110 (ML22011) - study

被引：0
|
作者：
Modest, D. P. [1 ]
von Weikersthal, Fischer L. [2 ]
Decker, T.
Vehling-Kaiser, U.
Uhlig, J.
Schenk, M. [3 ]
Freiberg-Richter, J.
Peuser, B.
Denzlinger, C. [4 ]
Reddemann, Peveling Genannt C. [5 ]
Graeven, U. [6 ]
Schuch, G. [7 ]
Schwaner, I. [8 ]
Stahler, A. [9 ]
Jung, A. [10 ]
Held, S. [11 ]
Stintzing, S. [9 ]
Giessen-Jung, C. [9 ]
Heinemann, V. [9 ]
机构：
[1] Klinikum Ludwig Maximilians Univ, Med Klin 3, Munich, Germany
[2] Gesundheitszentrum St Marien, Amberg, Germany
[3] Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany
[4] Marienhospital, Stuttgart, Germany
[5] MVZ RNR Leverkusen Gesundheitspk, Leverkusen, Germany
[6] Krankenhaus St Franziskus, Kliniken Maria Hilf GmbH, Monchengladbach, Germany
[7] HOPA, Hamburg, Germany
[8] Onkol Schwerpunktpraxis Kurfurstendamm, Berlin, Germany
[9] Klinikum Ludwig Maximilians Univ, Munich, Germany
[10] LMU, Inst Pathol, Munich, Germany
[11] ClinAssess GmbH, Leverkusen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V459
引用
收藏
页码：123 / 123
页数：1
相关论文
共 50 条
  • [1] Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.
    Dominik, Modest
    Ludwig, Fischer von Weikersthal
    Thomas, Decker
    Ursula, Vehling-Kaiser
    Jens, Uhlig
    Michael, Schenk
    Jens, Freiberg-Richter
    Bettina, Peuser
    Claudio, Denzlinger
    Christina, Peveling Genannt Reddemann
    Ullrich, Graeven
    Gunter, Schuch
    Ingo, Schwaner
    Arndt, Stahler
    Andreas, Jung
    Swantje, Held
    Sebastian, Stintzing
    Clemens, Giessen-Jung
    Volker, Heinemann
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Uhlig, J.
    Schenk, M.
    Freiberg-Richter, J.
    Peuser, B.
    Denzlinger, C.
    Reddemann, C. Peveling Genannt
    Graeven, U.
    Schuch, G.
    Schwaner, I.
    Stahler, A.
    Jung, A.
    Held, S.
    Stintzing, S.
    Giessen-Jung, C.
    Heinemann, V.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] Randomized Phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIOKRK0110-study
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Vehling-Kaiser, U.
    Graeven, U.
    Held, S.
    Stahler, A.
    Uhlig, J.
    Peuser, B.
    Freiberg-Richter, J.
    Denzlinger, C.
    Schwaner, I.
    Reddemann, C.
    Schuch, G.
    Schenk, M.
    Jung, A.
    Stintzing, S.
    Giessen-Jung, C.
    Heinemann, V.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 185 - 185
  • [4] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Giessen, Clemens
    von Weikersthal, Ludwig Fischer
    Hinke, Axel
    Stintzing, Sebastian
    Kullmann, Frank
    Vehling-Kaiser, Ursula
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Freiberg-Richter, Jens
    Schulz, Christoph
    Modest, Dominik Paul
    Moosmann, Nicolas
    Aubele, Philipp
    Heinemann, Volker
    [J]. BMC CANCER, 2011, 11
  • [5] A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
    Clemens Giessen
    Ludwig Fischer von Weikersthal
    Axel Hinke
    Sebastian Stintzing
    Frank Kullmann
    Ursula Vehling-Kaiser
    Julia Mayerle
    Markus Bangerter
    Claudio Denzlinger
    Markus Sieber
    Christian Teschendorf
    Jens Freiberg-Richter
    Christoph Schulz
    Dominik Paul Modest
    Nicolas Moosmann
    Philipp Aubele
    Volker Heinemann
    [J]. BMC Cancer, 11
  • [6] Sequential first-line treatment for metastatic colorectal cancer with capecitabine, irinotecan, and bevacizumab: Capecitabine plus bevacizumab (Cape-Bev) versus capecitabine, irinotecan plus bevacizumab (CAPIRI-Bev): The AIO KRK 0110/ML22011 randomized, phase III trial
    Giessen, Clemens Albrecht
    Modest, Dominik Paul
    Stintzing, Sebastian
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Spaeth-Schwalbe, Ernst
    Freiberg-Richter, Jens
    Mayerle, Julia
    Bangerter, Markus
    Denzlinger, Claudio
    Sieber, Markus
    Teschendorf, Christian
    Peuser, Bettina
    Heinemann, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study
    Hegewisch-Becker, S.
    Arnold, D.
    Lerchenmueller, C. A.
    Killing, B.
    Depenbusch, R.
    Steffens, C. -C
    Al-Batran, S. -E
    Lange, T.
    Dietrich, G.
    Stoehlmacher, J.
    Reinacher-Schick, A.
    Tannapfel, A.
    Quidde, J.
    Hinke, A.
    Schmoll, H. -J
    Graeven, U.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 99
  • [8] Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
    Arnold, Dirk
    Graeven, Ullrich
    Lerchenmuller, Christian A.
    Killing, Brigitta
    Depenbusch, Reinhard
    Steffens, Claus-Christoph
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Stoehimacher, Jan
    Tannapfel, Andrea
    Schmoll, Hans-Joachim
    Reinacher-Schick, Anke
    Hegewisch-Becker, Susanna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Fluoropyrimidine (FP) plus bevacizumab (BEV) plus atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
    Grothey, A.
    Tabernero, J.
    Arnold, D.
    De Gramont, A.
    Ducreux, M. P.
    O'Dwyer, P. J.
    Van Cutsem, E.
    Bosanac, I.
    Srock, S.
    Mancao, C.
    Gilberg, F.
    Winter, J.
    Schmoll, H-J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [10] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345